The Fanconi Anemia pathway, named after a cancer-predisposition syndrome, is essential for the repair of DNA-interstrand crosslinks (ICLs). The pathway consists of 22 FA complementation group proteins ...

The genetic basis of Fanconi anemia (FA) is mysterious and complex, as none of the five genes previously associated with the disorder have homology to genes encoding proteins of known function.

Their hunt narrowed to a set of genes involved in the Fanconi anemia pathway—a DNA repair mechanism mutated in an eponymous ...

RP-L102, Rocket's gene therapy in treatment of Fanconi Anemia, will likely have a BLA filing in Q4, 2024. In Pioneer, I pointed to the potential baked into its late-stage pipeline, while warning ...

The third and final risk to consider would be in terms of the regulatory filings and reviews of gene therapy RP-L102 for the treatment of patients with Fanconi Anemia [FA]. The risk here is that ...

In a touching tale of humanitarianism, Selva, an 11-year-old boy from Tiruchirappalli who survived Fanconi Anemia, met the ...

Rocket Pharmaceuticals, Inc. RCKT announced that it has completed patient enrollment in a pivotal phase II study evaluating ...

Niece of Jack (Lisa) Nash & Stephen Nash. Service & Interment Wheatland, WY. Contributions: Fanconi Anemia Research Fund. Click here to Send Flowers to the family of Teri. Published in ...

The community unites to host a music festival to fundraise for Dylan René, 6, and her father, Josiah Menard who are facing ...

Rocket’s lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF ...

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...

"These findings could eventually lead to new strategies incorporating Fanconi anemia pathway inhibition with other drugs to combat the emergence of therapy-resistant cancer cells, which represents ...